As the results for both ATP-competitive and allosteric inhibitors in clinical studies differ in patients with cancers of different genetic backgrounds, further studies are warranted to unravel the predictive biomarkers to maximize the therapeutic efficacies, to develop a precision treatment that utilizes AKT inhibitors. Here, AKT1 is linked to cancer.